Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.65 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.65 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.65 |
| ▸ | ADH1A | P07327 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 1/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | LDHA | P00338 | 1/20 | 0.71 |
| ▸ | LDHB | P07195 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8188 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL29350404 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL29740660 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL8187 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL8003782 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL1276381 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL29351291 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL29548827 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL20202727 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR | |
| SCHEMBL25792100 | 0.99 | ADH1A (1.00) | ADH1ALMNAPMP22TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62104595-A | — | — | None | — | — | JP | disclosed |
| US-20260102088-A1 | ANALYTE SENSORS FEATURING ENHANCEMENTS FOR DECREASING INTERFERENT SIGNAL | ABBOTT DIABETES CARE INC. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4687663-A1 | ASCORBATE BLOCKING MEMBRANE | Abbott Diabetes Care, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4679075-A2 | ANALYTE SENSORS FEATURING ONE OR MORE DETECTION-FACILITATING ENHANCEMENTS | Abbott Diabetes Care Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12465251-B2 | Analyte sensors featuring enhancements for decreasing interferent signal | ABBOTT DIABETES CARE INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250241568-A1 | ANALYTE SENSORS WITH REDUCED INTERFERENT SIGNAL AND METHODS | ABBOTT DIABETES CARE INC. (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025137203-A1 | GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY | ABBOTT DIABETES CARE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250194964-A1 | GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY | ABBOTT DIABETES CARE, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4558048-A1 | ANALYTE SENSORS WITH REDUCED INTERFERENT SIGNAL AND METHODS | Abbott Diabetes Care, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119584918-A | Analyte sensor and method with reduced interferent signal | 雅培糖尿病护理公司 | 2025-03-07 | — | — | CN | disclosed |
| US-7520970-B2 | Immobilization support, process for producing the same, electrode, process for producing the same, electrode reaction utilizing apparatus and process for producing the same | SONY CORPORATION (JP) | 2009-04-21 | — | — | US | disclosed |
| CN-1802434-A | Immobilization support, process for producing the same, electrode, process for producing the same, electrode reaction utilizing apparatus and process for producing the same | SONY CORP (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-20060105418-A1 | Immobilization support, process for producing the same, electrode, process for producing the same, electrode reaction utilizing apparatus and process for producing the same | MURATA MANUFACTURING CO., LTD. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1630227-A1 | IMMOBILIZATION SUPPORT, PROCESS FOR PRODUCING THE SAME, ELECTRODE, PROCESS FOR PRODUCING THE SAME, ELECTRODE REACTION UTILIZING APPARATUS AND PROCESS FOR PRODUCING THE SAME | Sony Corporation (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-5463047-A | Intermediates for the manufacture of 4-acyloxy-3-hydroxyethylazetidinones | CIBA-GEIGY CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| US-5386029-A | Process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones | CIBA-GEIGY CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
| US-5274188-A | Process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-5064761-A | PROCESS FOR THE MANUFACTURE OF 4-ACYLAMINO-3-HYDROXYBUTYRIC ACID ESTERS | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-4927507-A | Novel process for the manufacture of 4-acyloxy-3-hydroxyethyl-azetidinones | CIBA-GEIGY CORPORATION (US) | 1990-05-22 | — | — | US | disclosed |
| JP-S62104595-A | MEASUREMENT OF GLUCOSE | ORIENTAL YEAST CO LTD | 1987-05-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102088-A1 | ANALYTE SENSORS FEATURING ENHANCEMENTS FOR DECREASING INTERFERENT SIGNAL | IDE, PYGM, SLC2A8 | OPRM1 3695/4885OPRD1 4478/4885OPRK1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.